Literature DB >> 6809760

Evidence for the separation of albumin- and apo A-I-dependent mechanisms of cholesterol efflux from cultured fibroblasts into human plasma.

C J Fielding, K Moser.   

Abstract

The role of albumin has been studied in the plasma-mediated efflux of cholesterol from cultured fibroblasts. Immunoaffinity chromatography of plasma on immobilized anti-albumin antibody decreased by 25-50% total efflux catalyzed by plasma. The remainder of the efflux-promoting capacity of plasma was deleted by immunoaffinity chromatography on antibody to apolipoprotein A-I, the major apoprotein of high density lipoprotein. Both components of efflux were saturable with half-saturation at 0.5-1.0% (v/v) plasma. However, the net transport of sterol from cells to medium catalyzed by lecithin:cholesterol acyltransferase, was not reduced by the deletion of the albumin-catalyzed component of efflux. This finding was confirmed with congenitally analbuminemic plasma. These results indicate that efflux to albumin and to high density lipoprotein in plasma represent independent mechanisms; only the latter is coupled to net transport.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809760

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  HDL3-mediated cholesterol efflux from cultured enterocytes: the role of apoproteins A-I and A-II.

Authors:  G Herold; U Hesse; F Wisst; C Fahr; M Fahr; G Rogler; I Geerling; E F Stange
Journal:  Lipids       Date:  1994-11       Impact factor: 1.880

2.  Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome.

Authors:  Madhuri Vasudevan; Urbain Tchoua; Baiba K Gillard; Peter H Jones; Christie M Ballantyne; Henry J Pownall
Journal:  J Clin Lipidol       Date:  2013-05-25       Impact factor: 4.766

3.  Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.

Authors:  V Atger; M de la Llera Moya; M Bamberger; O Francone; P Cosgrove; A Tall; A Walsh; N Moatti; G Rothblat
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Serum albumin acts as a shuttle to enhance cholesterol efflux from cells.

Authors:  Sandhya Sankaranarayanan; Margarita de la Llera-Moya; Denise Drazul-Schrader; Michael C Phillips; Ginny Kellner-Weibel; George H Rothblat
Journal:  J Lipid Res       Date:  2013-01-03       Impact factor: 5.922

Review 5.  Fluorescence techniques using dehydroergosterol to study cholesterol trafficking.

Authors:  Avery L McIntosh; Barbara P Atshaves; Huan Huang; Adalberto M Gallegos; Ann B Kier; Friedhelm Schroeder
Journal:  Lipids       Date:  2008-06-07       Impact factor: 1.880

6.  Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux.

Authors:  Mary F Lopez; Bryan Krastins; David A Sarracino; Gregory Byram; Maryann S Vogelsang; Amol Prakash; Scott Peterman; Shadab Ahmad; Gouri Vadali; Wenjun Deng; Ignacio Inglessis; Tom Wickham; Kathleen Feeney; G William Dec; Igor Palacios; Ferdinando S Buonanno; Eng H Lo; MingMing Ning
Journal:  Clin Proteomics       Date:  2015-01-13       Impact factor: 3.988

Review 7.  Analysis of Low Molecular Weight Substances and Related Processes Influencing Cellular Cholesterol Efflux.

Authors:  Dmitry Y Litvinov; Eugeny V Savushkin; Alexander D Dergunov
Journal:  Pharmaceut Med       Date:  2019-12

8.  Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis.

Authors:  Bradley K Wacker; Nagadhara Dronadula; Jingwan Zhang; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-08       Impact factor: 8.311

Review 9.  Critical appraisal of the role of serum albumin in cardiovascular disease.

Authors:  Shih-Chieh Chien; Chun-Yen Chen; Chao-Feng Lin; Hung-I Yeh
Journal:  Biomark Res       Date:  2017-11-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.